Cargando…
Celecoxib as a Valuable Adjuvant in Cutaneous Melanoma Treated with Trametinib
Background: Melanoma patients stop responding to targeted therapies mainly due to mitogen activated protein kinase (MAPK) pathway re-activation, phosphoinositide 3 kinase/the mechanistic target of rapamycin (PI3K/mTOR) pathway activation or stromal cell influence. The future of melanoma treatment li...
Autores principales: | Tudor, Diana Valentina, Bâldea, Ioana, Olteanu, Diana Elena, Fischer-Fodor, Eva, Piroska, Virag, Lupu, Mihai, Călinici, Tudor, Decea, Roxana Maria, Filip, Gabriela Adriana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122835/ https://www.ncbi.nlm.nih.gov/pubmed/33922284 http://dx.doi.org/10.3390/ijms22094387 |
Ejemplares similares
-
Low Doses of Celecoxib Might Promote Phenotype Switching in Cutaneous Melanoma Treated with Dabrafenib—Preliminary Study
por: Tudor, Diana Valentina, et al.
Publicado: (2022) -
Photodynamic therapy of melanoma using new, synthetic porphyrins and phthalocyanines as photosensitisers – a comparative study
por: BALDEA, IOANA, et al.
Publicado: (2015) -
Combined regimen of photodynamic therapy mediated by Gallium phthalocyanine chloride and Metformin enhances anti-melanoma efficacy
por: Tudor, Diana, et al.
Publicado: (2017) -
COX-2 as a potential biomarker and therapeutic target in melanoma
por: Tudor, Diana Valentina, et al.
Publicado: (2020) -
Curcumin Reverses the Diazepam-Induced Cognitive Impairment by Modulation of Oxidative Stress and ERK 1/2/NF-κB Pathway in Brain
por: Sevastre-Berghian, Alexandra C., et al.
Publicado: (2017)